{
    "info": {
        "nct_id": "NCT06212583",
        "official_title": "A Randomized Trial of High-risK metachroNous oligometastatIc Prostate Cancer With hiGh-risk Mutations Treated witH meTastasiS Directed Therapy and Niraparib/Abiraterone Acetate and Prednisone (KNIGHTS)",
        "inclusion_criteria": "1. ≥18 years of age (or the local legal age of consent).\n2. Patient must have at least one and up to three asymptomatic metastatic tumor(s) of the bone, soft tissue, or extra-pelvic nodal region each < 5 cm or < 250 cm3 that develop within the past 6-months that are seen on imaging. A nodal lesion is defined to include nodal conglomerates located in the same nodal chain such that they can be treated in one SABR field. Up to five lesions are allowed on advanced functional imaging such as fluciclovine (Axumin), choline or Prostate Specific Membrane Antigen (PSMA) PET-CT scan.\n\n   1. CT or MRI scan within 6 months of enrollment\n   2. Bone scan within 6 months of enrollment\n   3. Fluciclovine (Axumin), choline, or PSMA PET-CT scan within 6 months of enrollment (PET-CT scan is reasonable for study entry imaging as an alternative to CT/MRI scan and bone scan)\n3. Must have a high-risk pathogenic mutation (TP53, BRCA1/2, PALB2, ATM, BRIP1, CHEK2, FANCA, RAD51B, RAD54L, MUTYH) by next generation sequencing. ATM mutation enrollment will be capped at 5% of the overall population.\n4. Histologic confirmation of prostate adenocarcinoma (primary or metastatic tumor).\n5. Patient may have had prior systemic therapy and/or ADT so long as testosterone is > 100 ng/dl prior to enrollment\n6. PSA > 0.5 but <50 at enrollment.\n7. Prostate Specific Antigen Doubling Time (PSADT) < 15 months\n8. Baseline testosterone > 100 ng/dl\n9. Patient must have a life expectancy ≥ 12 months.\n10. Patient must have an ECOG performance status ≤ 2.\n11. Adequate hematologic, renal, and hepatic function at screening defined as follows:\n\n    • Absolute neutrophil count ≥1.5 x 109/L\n\n    • Hemoglobin ≥9.0 g/dL, independent of transfusions for at least 28 days\n    * Platelet count ≥100 x 109/L\n    * Creatinine <2 x upper limit of normal (ULN)\n    * Serum potassium ≥3.5 mmol/L\n    * Serum total bilirubin ≤1.5× ULN or direct bilirubin ≤1 x ULN (Note: In participants with Gilbert's syndrome, if total bilirubin is >1.5 × ULN, measure direct and indirect bilirubin, and if direct bilirubin is ≤1.5 × ULN, participant may be eligible)\n    * AST or ALT ≤3 × ULN\n12. Patient must have the ability to understand and the willingness to sign a written informed consent document\n13. Able to swallow the study medication tablets whole.\n14. While on study medication and for 4 months following the last dose of study medication, a male participant must agree to use condom and an adequate contraception method for female partner (WOCBP) A male participant must agree not to donate sperm while on study treatment and for a minimum of 4 months following the last dose of study medication.\n\n<!-- -->\n\n1. Castration-resistant prostate cancer (CRPC).\n2. Prior radiation therapy to an overlapping site of a target lesion that would preclude further radiation therapy\n3. Spinal cord compression or impending spinal cord compression.\n4. Suspected intracranial and/or liver metastases (>10 mm in largest axis).\n5. Patient receiving any other investigational agents.\n6. Inability to receive any form of systemic therapy in the opinion of a treating medical oncologist.\n7. Unable to lie flat during or tolerate PET/MRI, PET/CT or SABR.\n8. Radiographical evidence of cranial parenchymal metastasis.\n9. Active second primary malignancy; AML/MDS in medical history.\n10. Uncontrolled hypertension and myocardial infarction/PE/cardiac failure in last 6 months.\n11. Prior treatment with PARP inhibitor\n12. Refusal to sign informed consent.\n13. Pathological finding consistent with small cell or neuroendocrine carcinoma of the prostate.\n14. History of adrenal dysfunction\n15. Long-term use of systemically administered corticosteroids (>5mg of prednisone or the equivalent) during the study is not allowed. Short-term use (≤4 weeks, including taper) and locally administered steroids (eg, inhaled, topical, ophthalmic, and intra-articular) are allowed, if clinically indicated.\n16. Active malignancies (ie, progressing or requiring treatment change in the last 24 months) other than the disease being treated under study. The only allowed exceptions are:\n\n    * non-muscle invasive bladder cancer.\n    * skin cancer (non-melanoma or melanoma) treated within the last 24 months that is considered completely cured.\n    * malignancy that is considered cured with minimal risk of recurrence.\n    * History or current diagnosis of MDS/AML.\n17. Current evidence within 6 months prior to randomization of any of the following:\n\n    • severe/unstable angina, myocardial infarction, symptomatic congestive heart failure,\n\n    • clinically significant arterial or venous thromboembolic events (ie. Pulmonary embolism), or clinically significant ventricular arrhythmias.\n18. Presence of sustained uncontrolled hypertension (systolic blood pressure >160 mm Hg or diastolic blood pressure >100 mm Hg). Participants with a history of hypertension are allowed, provided that blood pressure is controlled to within these limits by an antihypertensive treatment.\n19. Known allergies, hypersensitivity, or intolerance to the excipients of niraparib/abiraterone acetate tablets\n20. Current evidence of any medical condition that would make prednisone use contraindicated.\n21. Received an investigational intervention (including investigational vaccines) or used an invasive investigational medical device within 30 days before the planned first dose of study medication.\n22. Participants who have had the following ≤28 days prior to randomization:\n\n    • A transfusion (platelets or red blood cells);\n\n    • Hematopoietic growth factors;\n\n    • Major surgery\n23. Human immunodeficiency virus positive participants with 1 or more of the following:\n\n    • Not receiving highly active antiretroviral therapy or on antiretroviral therapy for less than 4 weeks.\n    * Receiving antiretroviral therapy that may interfere with the study medication\n    * CD4 count <350 at screening.\n    * An acquired immunodeficiency syndrome-defining opportunistic infection within 6 months of the start of screening.\n    * Human immunodeficiency virus load >400 copies/mL\n24. Active or symptomatic viral hepatitis or chronic liver disease; encephalopathy, ascites or bleeding disorders secondary to hepatic dysfunction.\n25. Moderate or severe hepatic impairment (Class B and C per Child-Pugh classification system.\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
        "exclusion_criteria": "",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "identified_line": {
                "line": "11. Adequate hematologic, renal, and hepatic function at screening defined as follows:",
                "criterions": [
                    {
                        "exact_snippets": "Adequate hematologic ... function at screening",
                        "criterion": "hematologic function",
                        "requirement": {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Adequate hematologic ... function at screening",
                        "criterion": "hematologic function",
                        "requirement": {
                            "requirement_type": "timepoint",
                            "expected_value": "at screening"
                        }
                    },
                    {
                        "exact_snippets": "Adequate ... renal ... function at screening",
                        "criterion": "renal function",
                        "requirement": {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Adequate ... renal ... function at screening",
                        "criterion": "renal function",
                        "requirement": {
                            "requirement_type": "timepoint",
                            "expected_value": "at screening"
                        }
                    },
                    {
                        "exact_snippets": "Adequate ... hepatic function at screening",
                        "criterion": "hepatic function",
                        "requirement": {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Adequate ... hepatic function at screening",
                        "criterion": "hepatic function",
                        "requirement": {
                            "requirement_type": "timepoint",
                            "expected_value": "at screening"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Adequate hematologic ... function at screening",
                                "criterion": "hematologic function",
                                "requirement": {
                                    "requirement_type": "adequacy",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Adequate hematologic ... function at screening",
                                "criterion": "hematologic function",
                                "requirement": {
                                    "requirement_type": "timepoint",
                                    "expected_value": "at screening"
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Adequate ... renal ... function at screening",
                                "criterion": "renal function",
                                "requirement": {
                                    "requirement_type": "adequacy",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Adequate ... renal ... function at screening",
                                "criterion": "renal function",
                                "requirement": {
                                    "requirement_type": "timepoint",
                                    "expected_value": "at screening"
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Adequate ... hepatic function at screening",
                                "criterion": "hepatic function",
                                "requirement": {
                                    "requirement_type": "adequacy",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Adequate ... hepatic function at screening",
                                "criterion": "hepatic function",
                                "requirement": {
                                    "requirement_type": "timepoint",
                                    "expected_value": "at screening"
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "8. Baseline testosterone > 100 ng/dl",
                "criterions": [
                    {
                        "exact_snippets": "Baseline testosterone > 100 ng/dl",
                        "criterion": "testosterone",
                        "requirement": {
                            "requirement_type": "baseline level",
                            "expected_value": {
                                "operator": ">",
                                "value": 100,
                                "unit": "ng/dl"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Baseline testosterone > 100 ng/dl",
                        "criterion": "testosterone",
                        "requirement": {
                            "requirement_type": "baseline level",
                            "expected_value": {
                                "operator": ">",
                                "value": 100,
                                "unit": "ng/dl"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "12. Patient must have the ability to understand and the willingness to sign a written informed consent document",
                "criterions": [
                    {
                        "exact_snippets": "ability to understand",
                        "criterion": "cognitive ability",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "willingness to sign a written informed consent document",
                        "criterion": "willingness to provide informed consent",
                        "requirement": {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "ability to understand",
                        "criterion": "cognitive ability",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "willingness to sign a written informed consent document",
                        "criterion": "willingness to provide informed consent",
                        "requirement": {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Serum total bilirubin ≤1.5× ULN or direct bilirubin ≤1 x ULN (Note: In participants with Gilbert's syndrome, if total bilirubin is >1.5 × ULN, measure direct and indirect bilirubin, and if direct bilirubin is ≤1.5 × ULN, participant may be eligible)",
                "criterions": [
                    {
                        "exact_snippets": "Serum total bilirubin ≤1.5× ULN",
                        "criterion": "serum total bilirubin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "direct bilirubin ≤1 x ULN",
                        "criterion": "direct bilirubin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "participants with Gilbert's syndrome, if total bilirubin is >1.5 × ULN, ... if direct bilirubin is ≤1.5 × ULN, participant may be eligible",
                        "criterion": "direct bilirubin in participants with Gilbert's syndrome and elevated total bilirubin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "ULN"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Serum total bilirubin ≤1.5× ULN",
                                "criterion": "serum total bilirubin",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 1.5,
                                        "unit": "ULN"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "direct bilirubin ≤1 x ULN",
                                "criterion": "direct bilirubin",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "ULN"
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "participants with Gilbert's syndrome, if total bilirubin is >1.5 × ULN, ... if direct bilirubin is ≤1.5 × ULN, participant may be eligible",
                        "criterion": "direct bilirubin in participants with Gilbert's syndrome and elevated total bilirubin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "ULN"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "13. Able to swallow the study medication tablets whole.",
                "criterions": [
                    {
                        "exact_snippets": "Able to swallow the study medication tablets whole",
                        "criterion": "ability to swallow study medication tablets whole",
                        "requirement": {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Able to swallow the study medication tablets whole",
                        "criterion": "ability to swallow study medication tablets whole",
                        "requirement": {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "2. Patient must have at least one and up to three asymptomatic metastatic tumor(s) of the bone, soft tissue, or extra-pelvic nodal region each < 5 cm or < 250 cm3 that develop within the past 6-months that are seen on imaging. A nodal lesion is defined to include nodal conglomerates located in the same nodal chain such that they can be treated in one SABR field. Up to five lesions are allowed on advanced functional imaging such as fluciclovine (Axumin), choline or Prostate Specific Membrane Antigen (PSMA) PET-CT scan.",
                "criterions": [
                    {
                        "exact_snippets": "at least one and up to three asymptomatic metastatic tumor(s) of the bone, soft tissue, or extra-pelvic nodal region",
                        "criterion": "number of asymptomatic metastatic tumors (bone, soft tissue, or extra-pelvic nodal region)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 1,
                                        "unit": "tumor"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": "tumor"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "each < 5 cm or < 250 cm3",
                        "criterion": "size of each metastatic tumor",
                        "requirement": {
                            "requirement_type": "size",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<",
                                        "value": 5,
                                        "unit": "cm"
                                    },
                                    {
                                        "operator": "<",
                                        "value": 250,
                                        "unit": "cm3"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "that develop within the past 6-months",
                        "criterion": "time since development of metastatic tumors",
                        "requirement": {
                            "requirement_type": "time since development",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "that are seen on imaging",
                        "criterion": "visibility of metastatic tumors on imaging",
                        "requirement": {
                            "requirement_type": "imaging visibility",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Up to five lesions are allowed on advanced functional imaging such as fluciclovine (Axumin), choline or Prostate Specific Membrane Antigen (PSMA) PET-CT scan.",
                        "criterion": "number of lesions on advanced functional imaging",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 5,
                                "unit": "lesion"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "at least one and up to three asymptomatic metastatic tumor(s) of the bone, soft tissue, or extra-pelvic nodal region",
                                "criterion": "number of asymptomatic metastatic tumors (bone, soft tissue, or extra-pelvic nodal region)",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "comparisons": [
                                            {
                                                "operator": ">=",
                                                "value": 1,
                                                "unit": "tumor"
                                            },
                                            {
                                                "operator": "<=",
                                                "value": 3,
                                                "unit": "tumor"
                                            }
                                        ]
                                    }
                                }
                            },
                            {
                                "exact_snippets": "each < 5 cm or < 250 cm3",
                                "criterion": "size of each metastatic tumor",
                                "requirement": {
                                    "requirement_type": "size",
                                    "expected_value": {
                                        "comparisons": [
                                            {
                                                "operator": "<",
                                                "value": 5,
                                                "unit": "cm"
                                            },
                                            {
                                                "operator": "<",
                                                "value": 250,
                                                "unit": "cm3"
                                            }
                                        ]
                                    }
                                }
                            },
                            {
                                "exact_snippets": "that develop within the past 6-months",
                                "criterion": "time since development of metastatic tumors",
                                "requirement": {
                                    "requirement_type": "time since development",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "that are seen on imaging",
                                "criterion": "visibility of metastatic tumors on imaging",
                                "requirement": {
                                    "requirement_type": "imaging visibility",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "Up to five lesions are allowed on advanced functional imaging such as fluciclovine (Axumin), choline or Prostate Specific Membrane Antigen (PSMA) PET-CT scan.",
                        "criterion": "number of lesions on advanced functional imaging",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 5,
                                "unit": "lesion"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "5. Patient may have had prior systemic therapy and/or ADT so long as testosterone is > 100 ng/dl prior to enrollment",
                "criterions": [
                    {
                        "exact_snippets": "Patient may have had prior systemic therapy and/or ADT",
                        "criterion": "prior systemic therapy and/or ADT",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "testosterone is > 100 ng/dl prior to enrollment",
                        "criterion": "testosterone level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 100,
                                "unit": "ng/dl"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "condition": {
                    "exact_snippets": "Patient may have had prior systemic therapy and/or ADT",
                    "criterion": "prior systemic therapy and/or ADT",
                    "requirement": {
                        "requirement_type": "history",
                        "expected_value": true
                    }
                },
                "then_criteria": {
                    "exact_snippets": "testosterone is > 100 ng/dl prior to enrollment",
                    "criterion": "testosterone level",
                    "requirement": {
                        "requirement_type": "quantity",
                        "expected_value": {
                            "operator": ">",
                            "value": 100,
                            "unit": "ng/dl"
                        }
                    }
                },
                "else_criteria": null
            }
        },
        {
            "identified_line": {
                "line": "1. Castration-resistant prostate cancer (CRPC).",
                "criterions": [
                    {
                        "exact_snippets": "Castration-resistant prostate cancer (CRPC)",
                        "criterion": "prostate cancer",
                        "requirement": {
                            "requirement_type": "disease subtype",
                            "expected_value": "castration-resistant"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Castration-resistant prostate cancer (CRPC)",
                        "criterion": "prostate cancer",
                        "requirement": {
                            "requirement_type": "disease subtype",
                            "expected_value": "castration-resistant"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "14. While on study medication and for 4 months following the last dose of study medication, a male participant must agree to use condom and an adequate contraception method for female partner (WOCBP) A male participant must agree not to donate sperm while on study treatment and for a minimum of 4 months following the last dose of study medication.",
                "criterions": [
                    {
                        "exact_snippets": "a male participant must agree to use condom and an adequate contraception method for female partner (WOCBP) ... While on study medication and for 4 months following the last dose of study medication",
                        "criterion": "contraception use by male participant",
                        "requirement": {
                            "requirement_type": "agreement to use condom",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "a male participant must agree to use condom and an adequate contraception method for female partner (WOCBP) ... While on study medication and for 4 months following the last dose of study medication",
                        "criterion": "contraception use by male participant",
                        "requirement": {
                            "requirement_type": "agreement to use adequate contraception method for female partner (WOCBP)",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "a male participant must agree to use condom and an adequate contraception method for female partner (WOCBP) ... While on study medication and for 4 months following the last dose of study medication",
                        "criterion": "contraception use by male participant",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "while on study medication"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 4,
                                        "unit": "months after last dose"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "A male participant must agree not to donate sperm while on study treatment and for a minimum of 4 months following the last dose of study medication",
                        "criterion": "sperm donation by male participant",
                        "requirement": {
                            "requirement_type": "agreement not to donate sperm",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "A male participant must agree not to donate sperm while on study treatment and for a minimum of 4 months following the last dose of study medication",
                        "criterion": "sperm donation by male participant",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "while on study treatment"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 4,
                                        "unit": "months after last dose"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "a male participant must agree to use condom and an adequate contraception method for female partner (WOCBP) ... While on study medication and for 4 months following the last dose of study medication",
                                "criterion": "contraception use by male participant",
                                "requirement": {
                                    "requirement_type": "agreement to use condom",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "a male participant must agree to use condom and an adequate contraception method for female partner (WOCBP) ... While on study medication and for 4 months following the last dose of study medication",
                                "criterion": "contraception use by male participant",
                                "requirement": {
                                    "requirement_type": "agreement to use adequate contraception method for female partner (WOCBP)",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "a male participant must agree to use condom and an adequate contraception method for female partner (WOCBP) ... While on study medication and for 4 months following the last dose of study medication",
                                "criterion": "contraception use by male participant",
                                "requirement": {
                                    "requirement_type": "duration",
                                    "expected_value": {
                                        "comparisons": [
                                            {
                                                "operator": ">=",
                                                "value": 0,
                                                "unit": "while on study medication"
                                            },
                                            {
                                                "operator": ">=",
                                                "value": 4,
                                                "unit": "months after last dose"
                                            }
                                        ]
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "A male participant must agree not to donate sperm while on study treatment and for a minimum of 4 months following the last dose of study medication",
                                "criterion": "sperm donation by male participant",
                                "requirement": {
                                    "requirement_type": "agreement not to donate sperm",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "A male participant must agree not to donate sperm while on study treatment and for a minimum of 4 months following the last dose of study medication",
                                "criterion": "sperm donation by male participant",
                                "requirement": {
                                    "requirement_type": "duration",
                                    "expected_value": {
                                        "comparisons": [
                                            {
                                                "operator": ">=",
                                                "value": 0,
                                                "unit": "while on study treatment"
                                            },
                                            {
                                                "operator": ">=",
                                                "value": 4,
                                                "unit": "months after last dose"
                                            }
                                        ]
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "20. Current evidence of any medical condition that would make prednisone use contraindicated.",
                "criterions": [
                    {
                        "exact_snippets": "Current evidence of any medical condition that would make prednisone use contraindicated.",
                        "criterion": "medical condition contraindicating prednisone use",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Current evidence of any medical condition that would make prednisone use contraindicated.",
                        "criterion": "medical condition contraindicating prednisone use",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "10. Patient must have an ECOG performance status ≤ 2.",
                "criterions": [
                    {
                        "exact_snippets": "ECOG performance status ≤ 2",
                        "criterion": "ECOG performance status",
                        "requirement": {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "ECOG performance status ≤ 2",
                        "criterion": "ECOG performance status",
                        "requirement": {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "14. History of adrenal dysfunction",
                "criterions": [
                    {
                        "exact_snippets": "History of adrenal dysfunction",
                        "criterion": "adrenal dysfunction",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "History of adrenal dysfunction",
                        "criterion": "adrenal dysfunction",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "1. CT or MRI scan within 6 months of enrollment",
                "criterions": [
                    {
                        "exact_snippets": "CT or MRI scan within 6 months of enrollment",
                        "criterion": "CT scan",
                        "requirement": {
                            "requirement_type": "time since scan",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "CT or MRI scan within 6 months of enrollment",
                        "criterion": "MRI scan",
                        "requirement": {
                            "requirement_type": "time since scan",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "CT or MRI scan within 6 months of enrollment",
                        "criterion": "CT scan",
                        "requirement": {
                            "requirement_type": "time since scan",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "CT or MRI scan within 6 months of enrollment",
                        "criterion": "MRI scan",
                        "requirement": {
                            "requirement_type": "time since scan",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "6. PSA > 0.5 but <50 at enrollment.",
                "criterions": [
                    {
                        "exact_snippets": "PSA > 0.5 but <50 at enrollment",
                        "criterion": "PSA",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">",
                                        "value": 0.5,
                                        "unit": ""
                                    },
                                    {
                                        "operator": "<",
                                        "value": 50,
                                        "unit": ""
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "PSA > 0.5 but <50 at enrollment",
                        "criterion": "PSA",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">",
                                        "value": 0.5,
                                        "unit": ""
                                    },
                                    {
                                        "operator": "<",
                                        "value": 50,
                                        "unit": ""
                                    }
                                ]
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "10. Uncontrolled hypertension and myocardial infarction/PE/cardiac failure in last 6 months.",
                "criterions": [
                    {
                        "exact_snippets": "Uncontrolled hypertension",
                        "criterion": "hypertension",
                        "requirement": {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    },
                    {
                        "exact_snippets": "myocardial infarction ... in last 6 months",
                        "criterion": "myocardial infarction",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "PE ... in last 6 months",
                        "criterion": "pulmonary embolism",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "cardiac failure in last 6 months",
                        "criterion": "cardiac failure",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Uncontrolled hypertension",
                                "criterion": "hypertension",
                                "requirement": {
                                    "requirement_type": "control status",
                                    "expected_value": "uncontrolled"
                                }
                            },
                            {
                                "exact_snippets": "myocardial infarction ... in last 6 months",
                                "criterion": "myocardial infarction",
                                "requirement": {
                                    "requirement_type": "recency",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Uncontrolled hypertension",
                                "criterion": "hypertension",
                                "requirement": {
                                    "requirement_type": "control status",
                                    "expected_value": "uncontrolled"
                                }
                            },
                            {
                                "exact_snippets": "PE ... in last 6 months",
                                "criterion": "pulmonary embolism",
                                "requirement": {
                                    "requirement_type": "recency",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Uncontrolled hypertension",
                                "criterion": "hypertension",
                                "requirement": {
                                    "requirement_type": "control status",
                                    "expected_value": "uncontrolled"
                                }
                            },
                            {
                                "exact_snippets": "cardiac failure in last 6 months",
                                "criterion": "cardiac failure",
                                "requirement": {
                                    "requirement_type": "recency",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Creatinine <2 x upper limit of normal (ULN)",
                "criterions": [
                    {
                        "exact_snippets": "Creatinine <2 x upper limit of normal (ULN)",
                        "criterion": "creatinine",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 2,
                                "unit": "x ULN"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Creatinine <2 x upper limit of normal (ULN)",
                        "criterion": "creatinine",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 2,
                                "unit": "x ULN"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* CD4 count <350 at screening.",
                "criterions": [
                    {
                        "exact_snippets": "CD4 count <350 at screening",
                        "criterion": "CD4 count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 350,
                                "unit": ""
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "CD4 count <350 at screening",
                        "criterion": "CD4 count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 350,
                                "unit": ""
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "3. Spinal cord compression or impending spinal cord compression.",
                "criterions": [
                    {
                        "exact_snippets": "Spinal cord compression",
                        "criterion": "spinal cord compression",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "impending spinal cord compression",
                        "criterion": "impending spinal cord compression",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Spinal cord compression",
                        "criterion": "spinal cord compression",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "impending spinal cord compression",
                        "criterion": "impending spinal cord compression",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "7. Unable to lie flat during or tolerate PET/MRI, PET/CT or SABR.",
                "criterions": [
                    {
                        "exact_snippets": "Unable to lie flat during or tolerate PET/MRI, PET/CT or SABR.",
                        "criterion": "ability to lie flat during PET/MRI, PET/CT or SABR",
                        "requirement": {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Unable to ... tolerate PET/MRI, PET/CT or SABR.",
                        "criterion": "ability to tolerate PET/MRI, PET/CT or SABR",
                        "requirement": {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Unable to lie flat during or tolerate PET/MRI, PET/CT or SABR.",
                        "criterion": "ability to lie flat during PET/MRI, PET/CT or SABR",
                        "requirement": {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Unable to ... tolerate PET/MRI, PET/CT or SABR.",
                        "criterion": "ability to tolerate PET/MRI, PET/CT or SABR",
                        "requirement": {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* AST or ALT ≤3 × ULN",
                "criterions": [
                    {
                        "exact_snippets": "AST or ALT ≤3 × ULN",
                        "criterion": "AST level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "AST or ALT ≤3 × ULN",
                        "criterion": "ALT level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "ULN"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "AST or ALT ≤3 × ULN",
                        "criterion": "AST level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "AST or ALT ≤3 × ULN",
                        "criterion": "ALT level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "ULN"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "8. Radiographical evidence of cranial parenchymal metastasis.",
                "criterions": [
                    {
                        "exact_snippets": "Radiographical evidence of cranial parenchymal metastasis",
                        "criterion": "cranial parenchymal metastasis",
                        "requirement": {
                            "requirement_type": "radiographical evidence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Radiographical evidence of cranial parenchymal metastasis",
                        "criterion": "cranial parenchymal metastasis",
                        "requirement": {
                            "requirement_type": "radiographical evidence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "9. Active second primary malignancy; AML/MDS in medical history.",
                "criterions": [
                    {
                        "exact_snippets": "Active second primary malignancy",
                        "criterion": "second primary malignancy",
                        "requirement": {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "AML/MDS in medical history",
                        "criterion": "AML/MDS",
                        "requirement": {
                            "requirement_type": "medical history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Active second primary malignancy",
                        "criterion": "second primary malignancy",
                        "requirement": {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "AML/MDS in medical history",
                        "criterion": "AML/MDS",
                        "requirement": {
                            "requirement_type": "medical history",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "• Major surgery",
                "criterions": [
                    {
                        "exact_snippets": "Major surgery",
                        "criterion": "major surgery",
                        "requirement": {
                            "requirement_type": "history/presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Major surgery",
                        "criterion": "major surgery",
                        "requirement": {
                            "requirement_type": "history/presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "2. Prior radiation therapy to an overlapping site of a target lesion that would preclude further radiation therapy",
                "criterions": [
                    {
                        "exact_snippets": "Prior radiation therapy to an overlapping site of a target lesion",
                        "criterion": "prior radiation therapy to overlapping site of target lesion",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "that would preclude further radiation therapy",
                        "criterion": "ability to receive further radiation therapy to overlapping site",
                        "requirement": {
                            "requirement_type": "eligibility for further radiation therapy",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Prior radiation therapy to an overlapping site of a target lesion",
                        "criterion": "prior radiation therapy to overlapping site of target lesion",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "that would preclude further radiation therapy",
                        "criterion": "ability to receive further radiation therapy to overlapping site",
                        "requirement": {
                            "requirement_type": "eligibility for further radiation therapy",
                            "expected_value": false
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "5. Patient receiving any other investigational agents.",
                "criterions": [
                    {
                        "exact_snippets": "Patient receiving any other investigational agents",
                        "criterion": "receipt of investigational agents",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Patient receiving any other investigational agents",
                        "criterion": "receipt of investigational agents",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "6. Inability to receive any form of systemic therapy in the opinion of a treating medical oncologist.",
                "criterions": [
                    {
                        "exact_snippets": "Inability to receive any form of systemic therapy in the opinion of a treating medical oncologist.",
                        "criterion": "ability to receive systemic therapy",
                        "requirement": {
                            "requirement_type": "ability",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "Inability to receive any form of systemic therapy in the opinion of a treating medical oncologist.",
                        "criterion": "ability to receive systemic therapy",
                        "requirement": {
                            "requirement_type": "determination by treating medical oncologist",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Inability to receive any form of systemic therapy in the opinion of a treating medical oncologist.",
                        "criterion": "ability to receive systemic therapy",
                        "requirement": {
                            "requirement_type": "ability",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "Inability to receive any form of systemic therapy in the opinion of a treating medical oncologist.",
                        "criterion": "ability to receive systemic therapy",
                        "requirement": {
                            "requirement_type": "determination by treating medical oncologist",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "7. Prostate Specific Antigen Doubling Time (PSADT) < 15 months",
                "criterions": [
                    {
                        "exact_snippets": "Prostate Specific Antigen Doubling Time (PSADT) < 15 months",
                        "criterion": "Prostate Specific Antigen Doubling Time (PSADT)",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "<",
                                "value": 15,
                                "unit": "months"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Prostate Specific Antigen Doubling Time (PSADT) < 15 months",
                        "criterion": "Prostate Specific Antigen Doubling Time (PSADT)",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "<",
                                "value": 15,
                                "unit": "months"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* History or current diagnosis of MDS/AML.",
                "criterions": [
                    {
                        "exact_snippets": "History or current diagnosis of MDS/AML.",
                        "criterion": "MDS/AML",
                        "requirement": {
                            "requirement_type": "history or current diagnosis",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "History or current diagnosis of MDS/AML.",
                        "criterion": "MDS/AML",
                        "requirement": {
                            "requirement_type": "history or current diagnosis",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "11. Prior treatment with PARP inhibitor",
                "criterions": [
                    {
                        "exact_snippets": "Prior treatment with PARP inhibitor",
                        "criterion": "prior treatment with PARP inhibitor",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Prior treatment with PARP inhibitor",
                        "criterion": "prior treatment with PARP inhibitor",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* malignancy that is considered cured with minimal risk of recurrence.",
                "criterions": [
                    {
                        "exact_snippets": "malignancy that is considered cured",
                        "criterion": "malignancy",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": "cured"
                        }
                    },
                    {
                        "exact_snippets": "minimal risk of recurrence",
                        "criterion": "risk of recurrence",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": "minimal"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "malignancy that is considered cured",
                        "criterion": "malignancy",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": "cured"
                        }
                    },
                    {
                        "exact_snippets": "minimal risk of recurrence",
                        "criterion": "risk of recurrence",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": "minimal"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "23. Human immunodeficiency virus positive participants with 1 or more of the following:",
                "criterions": [
                    {
                        "exact_snippets": "Human immunodeficiency virus positive participants",
                        "criterion": "HIV status",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Human immunodeficiency virus positive participants",
                        "criterion": "HIV status",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "• Hematopoietic growth factors;",
                "criterions": [
                    {
                        "exact_snippets": "Hematopoietic growth factors;",
                        "criterion": "hematopoietic growth factors",
                        "requirement": {
                            "requirement_type": "use or administration",
                            "expected_value": "N/A"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Hematopoietic growth factors;",
                        "criterion": "hematopoietic growth factors",
                        "requirement": {
                            "requirement_type": "use or administration",
                            "expected_value": "N/A"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "18. Presence of sustained uncontrolled hypertension (systolic blood pressure >160 mm Hg or diastolic blood pressure >100 mm Hg). Participants with a history of hypertension are allowed, provided that blood pressure is controlled to within these limits by an antihypertensive treatment.",
                "criterions": [
                    {
                        "exact_snippets": "Presence of sustained uncontrolled hypertension",
                        "criterion": "hypertension",
                        "requirement": {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    },
                    {
                        "exact_snippets": "Presence of sustained uncontrolled hypertension",
                        "criterion": "hypertension",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": "sustained"
                        }
                    },
                    {
                        "exact_snippets": "systolic blood pressure >160 mm Hg",
                        "criterion": "systolic blood pressure",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 160,
                                "unit": "mm Hg"
                            }
                        }
                    },
                    {
                        "exact_snippets": "diastolic blood pressure >100 mm Hg",
                        "criterion": "diastolic blood pressure",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 100,
                                "unit": "mm Hg"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Presence of sustained uncontrolled hypertension",
                                "criterion": "hypertension",
                                "requirement": {
                                    "requirement_type": "control status",
                                    "expected_value": "uncontrolled"
                                }
                            },
                            {
                                "exact_snippets": "Presence of sustained uncontrolled hypertension",
                                "criterion": "hypertension",
                                "requirement": {
                                    "requirement_type": "duration",
                                    "expected_value": "sustained"
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "systolic blood pressure >160 mm Hg",
                        "criterion": "systolic blood pressure",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 160,
                                "unit": "mm Hg"
                            }
                        }
                    },
                    {
                        "exact_snippets": "diastolic blood pressure >100 mm Hg",
                        "criterion": "diastolic blood pressure",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 100,
                                "unit": "mm Hg"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "16. Active malignancies (ie, progressing or requiring treatment change in the last 24 months) other than the disease being treated under study. The only allowed exceptions are:",
                "criterions": [
                    {
                        "exact_snippets": "Active malignancies (ie, progressing or requiring treatment change in the last 24 months) other than the disease being treated under study.",
                        "criterion": "malignancies other than the disease being treated under study",
                        "requirement": {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        }
                    },
                    {
                        "exact_snippets": "Active malignancies (ie, progressing or requiring treatment change in the last 24 months) other than the disease being treated under study.",
                        "criterion": "malignancies other than the disease being treated under study",
                        "requirement": {
                            "requirement_type": "progression or treatment change",
                            "expected_value": {
                                "operator": "<=",
                                "value": 24,
                                "unit": "months"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Active malignancies (ie, progressing or requiring treatment change in the last 24 months) other than the disease being treated under study.",
                                "criterion": "malignancies other than the disease being treated under study",
                                "requirement": {
                                    "requirement_type": "activity status",
                                    "expected_value": "active"
                                }
                            },
                            {
                                "exact_snippets": "Active malignancies (ie, progressing or requiring treatment change in the last 24 months) other than the disease being treated under study.",
                                "criterion": "malignancies other than the disease being treated under study",
                                "requirement": {
                                    "requirement_type": "progression or treatment change",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 24,
                                        "unit": "months"
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Human immunodeficiency virus load >400 copies/mL",
                "criterions": [
                    {
                        "exact_snippets": "Human immunodeficiency virus load >400 copies/mL",
                        "criterion": "human immunodeficiency virus (HIV) load",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 400,
                                "unit": "copies/mL"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Human immunodeficiency virus load >400 copies/mL",
                        "criterion": "human immunodeficiency virus (HIV) load",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 400,
                                "unit": "copies/mL"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Must be MALE",
                "criterions": [
                    {
                        "exact_snippets": "Must be MALE",
                        "criterion": "sex",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": "male"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Must be MALE",
                        "criterion": "sex",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": "male"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "17. Current evidence within 6 months prior to randomization of any of the following:",
                "criterions": [
                    {
                        "exact_snippets": "Current evidence within 6 months prior to randomization",
                        "criterion": "evidence of condition (unspecified)",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Current evidence within 6 months prior to randomization",
                        "criterion": "evidence of condition (unspecified)",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Current evidence within 6 months prior to randomization",
                        "criterion": "evidence of condition (unspecified)",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Current evidence within 6 months prior to randomization",
                        "criterion": "evidence of condition (unspecified)",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "21. Received an investigational intervention (including investigational vaccines) or used an invasive investigational medical device within 30 days before the planned first dose of study medication.",
                "criterions": [
                    {
                        "exact_snippets": "Received an investigational intervention (including investigational vaccines) ... within 30 days before the planned first dose of study medication.",
                        "criterion": "investigational intervention",
                        "requirement": {
                            "requirement_type": "receipt",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Received an investigational intervention (including investigational vaccines) ... within 30 days before the planned first dose of study medication.",
                        "criterion": "investigational intervention",
                        "requirement": {
                            "requirement_type": "time since receipt",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "used an invasive investigational medical device within 30 days before the planned first dose of study medication.",
                        "criterion": "invasive investigational medical device",
                        "requirement": {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "used an invasive investigational medical device within 30 days before the planned first dose of study medication.",
                        "criterion": "invasive investigational medical device",
                        "requirement": {
                            "requirement_type": "time since use",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Received an investigational intervention (including investigational vaccines) ... within 30 days before the planned first dose of study medication.",
                                "criterion": "investigational intervention",
                                "requirement": {
                                    "requirement_type": "receipt",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Received an investigational intervention (including investigational vaccines) ... within 30 days before the planned first dose of study medication.",
                                "criterion": "investigational intervention",
                                "requirement": {
                                    "requirement_type": "time since receipt",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 30,
                                        "unit": "days"
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "used an invasive investigational medical device within 30 days before the planned first dose of study medication.",
                                "criterion": "invasive investigational medical device",
                                "requirement": {
                                    "requirement_type": "use",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "used an invasive investigational medical device within 30 days before the planned first dose of study medication.",
                                "criterion": "invasive investigational medical device",
                                "requirement": {
                                    "requirement_type": "time since use",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 30,
                                        "unit": "days"
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "• clinically significant arterial or venous thromboembolic events (ie. Pulmonary embolism), or clinically significant ventricular arrhythmias.",
                "criterions": [
                    {
                        "exact_snippets": "clinically significant arterial or venous thromboembolic events (ie. Pulmonary embolism)",
                        "criterion": "arterial or venous thromboembolic events",
                        "requirement": {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "clinically significant ventricular arrhythmias",
                        "criterion": "ventricular arrhythmias",
                        "requirement": {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "clinically significant arterial or venous thromboembolic events (ie. Pulmonary embolism)",
                        "criterion": "arterial or venous thromboembolic events",
                        "requirement": {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "clinically significant ventricular arrhythmias",
                        "criterion": "ventricular arrhythmias",
                        "requirement": {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "22. Participants who have had the following ≤28 days prior to randomization:",
                "criterions": [
                    {
                        "exact_snippets": "Participants who have had the following ≤28 days prior to randomization",
                        "criterion": "receipt of specified interventions or events",
                        "requirement": {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Participants who have had the following ≤28 days prior to randomization",
                        "criterion": "receipt of specified interventions or events",
                        "requirement": {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "• Not receiving highly active antiretroviral therapy or on antiretroviral therapy for less than 4 weeks.",
                "criterions": [
                    {
                        "exact_snippets": "Not receiving highly active antiretroviral therapy",
                        "criterion": "highly active antiretroviral therapy (HAART)",
                        "requirement": {
                            "requirement_type": "treatment status",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "on antiretroviral therapy for less than 4 weeks",
                        "criterion": "antiretroviral therapy duration",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": "<",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Not receiving highly active antiretroviral therapy",
                        "criterion": "highly active antiretroviral therapy (HAART)",
                        "requirement": {
                            "requirement_type": "treatment status",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "on antiretroviral therapy for less than 4 weeks",
                        "criterion": "antiretroviral therapy duration",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": "<",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "2. Bone scan within 6 months of enrollment",
                "criterions": [
                    {
                        "exact_snippets": "Bone scan within 6 months of enrollment",
                        "criterion": "bone scan",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months before enrollment"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Bone scan within 6 months of enrollment",
                        "criterion": "bone scan",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months before enrollment"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "19. Known allergies, hypersensitivity, or intolerance to the excipients of niraparib/abiraterone acetate tablets",
                "criterions": [
                    {
                        "exact_snippets": "Known allergies, hypersensitivity, or intolerance to the excipients of niraparib/abiraterone acetate tablets",
                        "criterion": "allergies to excipients of niraparib/abiraterone acetate tablets",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Known allergies, hypersensitivity, or intolerance to the excipients of niraparib/abiraterone acetate tablets",
                        "criterion": "hypersensitivity to excipients of niraparib/abiraterone acetate tablets",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Known allergies, hypersensitivity, or intolerance to the excipients of niraparib/abiraterone acetate tablets",
                        "criterion": "intolerance to excipients of niraparib/abiraterone acetate tablets",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Known allergies, hypersensitivity, or intolerance to the excipients of niraparib/abiraterone acetate tablets",
                        "criterion": "allergies to excipients of niraparib/abiraterone acetate tablets",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Known allergies, hypersensitivity, or intolerance to the excipients of niraparib/abiraterone acetate tablets",
                        "criterion": "hypersensitivity to excipients of niraparib/abiraterone acetate tablets",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Known allergies, hypersensitivity, or intolerance to the excipients of niraparib/abiraterone acetate tablets",
                        "criterion": "intolerance to excipients of niraparib/abiraterone acetate tablets",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "24. Active or symptomatic viral hepatitis or chronic liver disease; encephalopathy, ascites or bleeding disorders secondary to hepatic dysfunction.",
                "criterions": [
                    {
                        "exact_snippets": "Active or symptomatic viral hepatitis",
                        "criterion": "viral hepatitis",
                        "requirement": {
                            "requirement_type": "activity or symptom presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "chronic liver disease",
                        "criterion": "chronic liver disease",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "encephalopathy ... secondary to hepatic dysfunction",
                        "criterion": "encephalopathy secondary to hepatic dysfunction",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "ascites ... secondary to hepatic dysfunction",
                        "criterion": "ascites secondary to hepatic dysfunction",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "bleeding disorders secondary to hepatic dysfunction",
                        "criterion": "bleeding disorders secondary to hepatic dysfunction",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Active or symptomatic viral hepatitis",
                                "criterion": "viral hepatitis",
                                "requirement": {
                                    "requirement_type": "activity or symptom presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "chronic liver disease",
                                "criterion": "chronic liver disease",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "encephalopathy ... secondary to hepatic dysfunction",
                        "criterion": "encephalopathy secondary to hepatic dysfunction",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "ascites ... secondary to hepatic dysfunction",
                        "criterion": "ascites secondary to hepatic dysfunction",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "bleeding disorders secondary to hepatic dysfunction",
                        "criterion": "bleeding disorders secondary to hepatic dysfunction",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "<!-- -->",
                "criterions": []
            },
            "logical_structure": {
                "and_criteria": []
            }
        },
        {
            "identified_line": {
                "line": "12. Refusal to sign informed consent.",
                "criterions": [
                    {
                        "exact_snippets": "Refusal to sign informed consent",
                        "criterion": "informed consent",
                        "requirement": {
                            "requirement_type": "signed",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Refusal to sign informed consent",
                        "criterion": "informed consent",
                        "requirement": {
                            "requirement_type": "signed",
                            "expected_value": false
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "• severe/unstable angina, myocardial infarction, symptomatic congestive heart failure,",
                "criterions": [
                    {
                        "exact_snippets": "severe/unstable angina",
                        "criterion": "angina",
                        "requirement": {
                            "requirement_type": "severity/stability",
                            "expected_value": "severe or unstable"
                        }
                    },
                    {
                        "exact_snippets": "myocardial infarction",
                        "criterion": "myocardial infarction",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "symptomatic congestive heart failure",
                        "criterion": "congestive heart failure",
                        "requirement": {
                            "requirement_type": "symptomatic",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "severe/unstable angina",
                        "criterion": "angina",
                        "requirement": {
                            "requirement_type": "severity/stability",
                            "expected_value": "severe or unstable"
                        }
                    },
                    {
                        "exact_snippets": "myocardial infarction",
                        "criterion": "myocardial infarction",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "symptomatic congestive heart failure",
                        "criterion": "congestive heart failure",
                        "requirement": {
                            "requirement_type": "symptomatic",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "4. Suspected intracranial and/or liver metastases (>10 mm in largest axis).",
                "criterions": [
                    {
                        "exact_snippets": "Suspected intracranial ... metastases (>10 mm in largest axis)",
                        "criterion": "intracranial metastases",
                        "requirement": {
                            "requirement_type": "suspicion",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Suspected intracranial ... metastases (>10 mm in largest axis)",
                        "criterion": "intracranial metastases",
                        "requirement": {
                            "requirement_type": "size",
                            "expected_value": {
                                "operator": ">",
                                "value": 10,
                                "unit": "mm"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Suspected ... liver metastases (>10 mm in largest axis)",
                        "criterion": "liver metastases",
                        "requirement": {
                            "requirement_type": "suspicion",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Suspected ... liver metastases (>10 mm in largest axis)",
                        "criterion": "liver metastases",
                        "requirement": {
                            "requirement_type": "size",
                            "expected_value": {
                                "operator": ">",
                                "value": 10,
                                "unit": "mm"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Suspected intracranial ... metastases (>10 mm in largest axis)",
                                "criterion": "intracranial metastases",
                                "requirement": {
                                    "requirement_type": "suspicion",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Suspected intracranial ... metastases (>10 mm in largest axis)",
                                "criterion": "intracranial metastases",
                                "requirement": {
                                    "requirement_type": "size",
                                    "expected_value": {
                                        "operator": ">",
                                        "value": 10,
                                        "unit": "mm"
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Suspected ... liver metastases (>10 mm in largest axis)",
                                "criterion": "liver metastases",
                                "requirement": {
                                    "requirement_type": "suspicion",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Suspected ... liver metastases (>10 mm in largest axis)",
                                "criterion": "liver metastases",
                                "requirement": {
                                    "requirement_type": "size",
                                    "expected_value": {
                                        "operator": ">",
                                        "value": 10,
                                        "unit": "mm"
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Receiving antiretroviral therapy that may interfere with the study medication",
                "criterions": [
                    {
                        "exact_snippets": "Receiving antiretroviral therapy that may interfere with the study medication",
                        "criterion": "antiretroviral therapy",
                        "requirement": {
                            "requirement_type": "current use",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Receiving antiretroviral therapy that may interfere with the study medication",
                        "criterion": "antiretroviral therapy",
                        "requirement": {
                            "requirement_type": "potential for drug interaction with study medication",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Receiving antiretroviral therapy that may interfere with the study medication",
                        "criterion": "antiretroviral therapy",
                        "requirement": {
                            "requirement_type": "current use",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Receiving antiretroviral therapy that may interfere with the study medication",
                        "criterion": "antiretroviral therapy",
                        "requirement": {
                            "requirement_type": "potential for drug interaction with study medication",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* non-muscle invasive bladder cancer.",
                "criterions": [
                    {
                        "exact_snippets": "non-muscle invasive bladder cancer",
                        "criterion": "bladder cancer",
                        "requirement": {
                            "requirement_type": "invasiveness",
                            "expected_value": "non-muscle invasive"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "non-muscle invasive bladder cancer",
                        "criterion": "bladder cancer",
                        "requirement": {
                            "requirement_type": "invasiveness",
                            "expected_value": "non-muscle invasive"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Must have minimum age of 18 Years",
                "criterions": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* An acquired immunodeficiency syndrome-defining opportunistic infection within 6 months of the start of screening.",
                "criterions": [
                    {
                        "exact_snippets": "An acquired immunodeficiency syndrome-defining opportunistic infection within 6 months of the start of screening.",
                        "criterion": "acquired immunodeficiency syndrome-defining opportunistic infection",
                        "requirement": {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "An acquired immunodeficiency syndrome-defining opportunistic infection within 6 months of the start of screening.",
                        "criterion": "acquired immunodeficiency syndrome-defining opportunistic infection",
                        "requirement": {
                            "requirement_type": "time_reference",
                            "expected_value": "start of screening"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "An acquired immunodeficiency syndrome-defining opportunistic infection within 6 months of the start of screening.",
                        "criterion": "acquired immunodeficiency syndrome-defining opportunistic infection",
                        "requirement": {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "An acquired immunodeficiency syndrome-defining opportunistic infection within 6 months of the start of screening.",
                        "criterion": "acquired immunodeficiency syndrome-defining opportunistic infection",
                        "requirement": {
                            "requirement_type": "time_reference",
                            "expected_value": "start of screening"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Healthy volunteers allowed",
                "criterions": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            }
        }
    ],
    "exclusion_lines": [],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "identified_line": {
                "line": "1. ≥18 years of age (or the local legal age of consent).",
                "criterions": [
                    {
                        "exact_snippets": "≥18 years of age (or the local legal age of consent)",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    },
                    {
                        "exact_snippets": "≥18 years of age (or the local legal age of consent)",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum age",
                            "expected_value": "local legal age of consent"
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "\u001e18 years of age (or the local legal age of consent)",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    },
                    {
                        "exact_snippets": "\u001e18 years of age (or the local legal age of consent)",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum age",
                            "expected_value": "local legal age of consent"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "3. Fluciclovine (Axumin), choline, or PSMA PET-CT scan within 6 months of enrollment (PET-CT scan is reasonable for study entry imaging as an alternative to CT/MRI scan and bone scan)",
                "criterions": [
                    {
                        "exact_snippets": "Fluciclovine (Axumin), choline, or PSMA PET-CT scan within 6 months of enrollment",
                        "criterion": "PET-CT scan (Fluciclovine, choline, or PSMA)",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Fluciclovine (Axumin), choline, or PSMA PET-CT scan within 6 months of enrollment",
                        "criterion": "PET-CT scan (Fluciclovine, choline, or PSMA)",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "PET-CT scan is reasonable for study entry imaging as an alternative to CT/MRI scan and bone scan",
                        "criterion": "study entry imaging",
                        "requirement": {
                            "requirement_type": "modality",
                            "expected_value": [
                                "PET-CT scan",
                                "CT/MRI scan",
                                "bone scan"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "9. Patient must have a life expectancy ≥ 12 months.",
                "criterions": [
                    {
                        "exact_snippets": "life expectancy ≥ 12 months",
                        "criterion": "life expectancy",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "life expectancy \u0013e 12 months",
                        "criterion": "life expectancy",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "3. Must have a high-risk pathogenic mutation (TP53, BRCA1/2, PALB2, ATM, BRIP1, CHEK2, FANCA, RAD51B, RAD54L, MUTYH) by next generation sequencing. ATM mutation enrollment will be capped at 5% of the overall population.",
                "criterions": [
                    {
                        "exact_snippets": "Must have a high-risk pathogenic mutation (TP53, BRCA1/2, PALB2, ATM, BRIP1, CHEK2, FANCA, RAD51B, RAD54L, MUTYH) by next generation sequencing",
                        "criterion": "high-risk pathogenic mutation in specified genes",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Must have a high-risk pathogenic mutation (TP53, BRCA1/2, PALB2, ATM, BRIP1, CHEK2, FANCA, RAD51B, RAD54L, MUTYH) by next generation sequencing",
                        "criterion": "high-risk pathogenic mutation in specified genes",
                        "requirement": {
                            "requirement_type": "genes",
                            "expected_value": [
                                "TP53",
                                "BRCA1",
                                "BRCA2",
                                "PALB2",
                                "ATM",
                                "BRIP1",
                                "CHEK2",
                                "FANCA",
                                "RAD51B",
                                "RAD54L",
                                "MUTYH"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "Must have a high-risk pathogenic mutation (TP53, BRCA1/2, PALB2, ATM, BRIP1, CHEK2, FANCA, RAD51B, RAD54L, MUTYH) by next generation sequencing",
                        "criterion": "high-risk pathogenic mutation in specified genes",
                        "requirement": {
                            "requirement_type": "detection_method",
                            "expected_value": "next generation sequencing"
                        }
                    },
                    {
                        "exact_snippets": "ATM mutation enrollment will be capped at 5% of the overall population",
                        "criterion": "ATM mutation enrollment",
                        "requirement": {
                            "requirement_type": "enrollment_cap",
                            "expected_value": {
                                "operator": "<=",
                                "value": 5,
                                "unit": "% of overall population"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "• Absolute neutrophil count ≥1.5 x 109/L",
                "criterions": [
                    {
                        "exact_snippets": "Absolute neutrophil count ≥1.5 x 109/L",
                        "criterion": "absolute neutrophil count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1.5,
                                "unit": "x 10^9/L"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Absolute neutrophil count \u00191.5 x 109/L",
                        "criterion": "absolute neutrophil count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1.5,
                                "unit": "x 10^9/L"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "4. Histologic confirmation of prostate adenocarcinoma (primary or metastatic tumor).",
                "criterions": [
                    {
                        "exact_snippets": "Histologic confirmation of prostate adenocarcinoma (primary or metastatic tumor)",
                        "criterion": "prostate adenocarcinoma",
                        "requirement": {
                            "requirement_type": "histologic confirmation",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "primary or metastatic tumor",
                        "criterion": "tumor location",
                        "requirement": {
                            "requirement_type": "location",
                            "expected_value": [
                                "primary",
                                "metastatic"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Platelet count ≥100 x 109/L",
                "criterions": [
                    {
                        "exact_snippets": "Platelet count ≥100 x 109/L",
                        "criterion": "platelet count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100,
                                "unit": "x 10^9/L"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Platelet count \u001e=100 x 109/L",
                        "criterion": "platelet count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100,
                                "unit": "x 10^9/L"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "• A transfusion (platelets or red blood cells);",
                "criterions": [
                    {
                        "exact_snippets": "A transfusion (platelets or red blood cells)",
                        "criterion": "transfusion",
                        "requirement": {
                            "requirement_type": "type",
                            "expected_value": [
                                "platelets",
                                "red blood cells"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "• Hemoglobin ≥9.0 g/dL, independent of transfusions for at least 28 days",
                "criterions": [
                    {
                        "exact_snippets": "Hemoglobin ≥9.0 g/dL",
                        "criterion": "hemoglobin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 9.0,
                                "unit": "g/dL"
                            }
                        }
                    },
                    {
                        "exact_snippets": "independent of transfusions for at least 28 days",
                        "criterion": "transfusion independence",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Hemoglobin \u001e9.0 g/dL",
                        "criterion": "hemoglobin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 9.0,
                                "unit": "g/dL"
                            }
                        }
                    },
                    {
                        "exact_snippets": "independent of transfusions for at least 28 days",
                        "criterion": "transfusion independence",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "13. Pathological finding consistent with small cell or neuroendocrine carcinoma of the prostate.",
                "criterions": [
                    {
                        "exact_snippets": "Pathological finding consistent with small cell or neuroendocrine carcinoma of the prostate.",
                        "criterion": "pathological finding",
                        "requirement": {
                            "requirement_type": "consistency with diagnosis",
                            "expected_value": [
                                "small cell carcinoma of the prostate",
                                "neuroendocrine carcinoma of the prostate"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Serum potassium ≥3.5 mmol/L",
                "criterions": [
                    {
                        "exact_snippets": "Serum potassium ≥3.5 mmol/L",
                        "criterion": "serum potassium",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3.5,
                                "unit": "mmol/L"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Serum potassium \u00193.5 mmol/L",
                        "criterion": "serum potassium",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3.5,
                                "unit": "mmol/L"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "25. Moderate or severe hepatic impairment (Class B and C per Child-Pugh classification system.",
                "criterions": [
                    {
                        "exact_snippets": "Moderate or severe hepatic impairment (Class B and C per Child-Pugh classification system",
                        "criterion": "hepatic impairment",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": [
                                "moderate",
                                "severe"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "Moderate or severe hepatic impairment (Class B and C per Child-Pugh classification system",
                        "criterion": "hepatic impairment",
                        "requirement": {
                            "requirement_type": "classification",
                            "expected_value": {
                                "operator": "=",
                                "value": 2,
                                "unit": "Child-Pugh class (B or C)"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* skin cancer (non-melanoma or melanoma) treated within the last 24 months that is considered completely cured.",
                "criterions": [
                    {
                        "exact_snippets": "skin cancer (non-melanoma or melanoma)",
                        "criterion": "skin cancer",
                        "requirement": {
                            "requirement_type": "type",
                            "expected_value": [
                                "non-melanoma",
                                "melanoma"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "treated within the last 24 months",
                        "criterion": "skin cancer treatment",
                        "requirement": {
                            "requirement_type": "time since treatment",
                            "expected_value": {
                                "operator": "<=",
                                "value": 24,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "considered completely cured",
                        "criterion": "skin cancer status",
                        "requirement": {
                            "requirement_type": "cure status",
                            "expected_value": "completely cured"
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "15. Long-term use of systemically administered corticosteroids (>5mg of prednisone or the equivalent) during the study is not allowed. Short-term use (≤4 weeks, including taper) and locally administered steroids (eg, inhaled, topical, ophthalmic, and intra-articular) are allowed, if clinically indicated.",
                "criterions": [
                    {
                        "exact_snippets": "Long-term use of systemically administered corticosteroids (>5mg of prednisone or the equivalent) during the study is not allowed.",
                        "criterion": "systemically administered corticosteroid use",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": "long-term"
                        }
                    },
                    {
                        "exact_snippets": "Long-term use of systemically administered corticosteroids (>5mg of prednisone or the equivalent) during the study is not allowed.",
                        "criterion": "systemically administered corticosteroid use",
                        "requirement": {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": ">",
                                "value": 5,
                                "unit": "mg prednisone or equivalent"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Long-term use of systemically administered corticosteroids (>5mg of prednisone or the equivalent) during the study is not allowed.",
                        "criterion": "systemically administered corticosteroid use",
                        "requirement": {
                            "requirement_type": "allowance",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "Short-term use (≤4 weeks, including taper) and locally administered steroids (eg, inhaled, topical, ophthalmic, and intra-articular) are allowed, if clinically indicated.",
                        "criterion": "systemically administered corticosteroid use",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Short-term use (≤4 weeks, including taper) and locally administered steroids (eg, inhaled, topical, ophthalmic, and intra-articular) are allowed, if clinically indicated.",
                        "criterion": "systemically administered corticosteroid use",
                        "requirement": {
                            "requirement_type": "allowance",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "locally administered steroids (eg, inhaled, topical, ophthalmic, and intra-articular) are allowed, if clinically indicated.",
                        "criterion": "locally administered steroid use",
                        "requirement": {
                            "requirement_type": "allowance",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "not_criteria": {
                            "and_criteria": [
                                {
                                    "and_criteria": [
                                        {
                                            "exact_snippets": "Long-term use of systemically administered corticosteroids (>5mg of prednisone or the equivalent) during the study is not allowed.",
                                            "criterion": "systemically administered corticosteroid use",
                                            "requirement": {
                                                "requirement_type": "duration",
                                                "expected_value": "long-term"
                                            }
                                        },
                                        {
                                            "exact_snippets": "Long-term use of systemically administered corticosteroids (>5mg of prednisone or the equivalent) during the study is not allowed.",
                                            "criterion": "systemically administered corticosteroid use",
                                            "requirement": {
                                                "requirement_type": "dose",
                                                "expected_value": {
                                                    "operator": ">",
                                                    "value": 5,
                                                    "unit": "mg prednisone or equivalent"
                                                }
                                            }
                                        }
                                    ]
                                }
                            ]
                        }
                    },
                    {
                        "or_criteria": [
                            {
                                "and_criteria": [
                                    {
                                        "exact_snippets": "Short-term use (≤4 weeks, including taper) and locally administered steroids (eg, inhaled, topical, ophthalmic, and intra-articular) are allowed, if clinically indicated.",
                                        "criterion": "systemically administered corticosteroid use",
                                        "requirement": {
                                            "requirement_type": "duration",
                                            "expected_value": {
                                                "operator": "<=",
                                                "value": 4,
                                                "unit": "weeks"
                                            }
                                        }
                                    },
                                    {
                                        "exact_snippets": "Short-term use (≤4 weeks, including taper) and locally administered steroids (eg, inhaled, topical, ophthalmic, and intra-articular) are allowed, if clinically indicated.",
                                        "criterion": "systemically administered corticosteroid use",
                                        "requirement": {
                                            "requirement_type": "allowance",
                                            "expected_value": true
                                        }
                                    }
                                ]
                            },
                            {
                                "exact_snippets": "locally administered steroids (eg, inhaled, topical, ophthalmic, and intra-articular) are allowed, if clinically indicated.",
                                "criterion": "locally administered steroid use",
                                "requirement": {
                                    "requirement_type": "allowance",
                                    "expected_value": true
                                }
                            }
                        ]
                    }
                ]
            }
        }
    ],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}